Airway dysbiosis accelerates lung function decline in chronic obstructive pulmonary disease.

Progressive lung function decline is a hallmark of chronic obstructive pulmonary disease (COPD). Airway dysbiosis occurs in COPD, but whether it contributes to disease progression remains unknown. Here, we show, through a longitudinal analysis of two cohorts involving four UK centers, that baseline airway dysbiosis in COPD patients, characterized by the enrichment of opportunistic pathogenic taxa, associates with a rapid forced expiratory volume in 1 s (FEV

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests B.E.M. was an employee of GlaxoSmithKline (GSK) at the time of this study and is a current shareholder, outside the submitted work. R.T.-S. was an employee of GSK at the time of this study and is a current shareholder, reports personal fees from Immunomet, Vocalis Health, Teva, and Ena Therapeutics, and reports share options in ENA Respiratory, outside the submitted work. G.C.D. reports grants and personal fees from AstraZeneca and grants from Micom Ltd. and American Thoracic Society, outside the submitted work. J.A.W. reports grants from GSK, Johnson and Johnson, Novartis, Boehringer Ingelheim, and AstraZeneca, outside the submitted work. D.S. reports grants and personal fees from AstraZeneca, Boehringer Ingleheim, Chiesi, CSL Behring, EpiEndo, GSK, Kinaset Therapeutics, Novartis, Pulmatrix, Sanofi, Therevance and Verona, personal fees from Aerogen, Cipla, Genentech, Glenmark, Menarini, and Pfizer and Teva, outside the submitted work. T.M.A.W. reports grants and personal fees from AstraZeneca, GSK, Janssen, Sanofi, and Synairgen, personal fees from Boehringer Ingelheim, OM Pharma and MMH, outside the submitted work. C.E.B. reports grants and personal fees from 4DPharma, AstraZeneca/MedImmune, Boehringer Ingelheim, Chiesi, Genentech, Gossamer, GSK, Mologics, Novartis, Regeneron, Sanofi, and Teva, outside the submitted work.